Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral AIMDAI +1.91%6 3-Year EBITDA Growth Rate is -8.70% as of Jun. 2026. GuruFocus rates MDAI with a GF Score™ of 6/100 and a GF Value™ of $0.83 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Spectral AI ranks worse than 75.8% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Spectral AI was -8.70% per year. The lowest was -34.10% per year. And the median was -21.40% per year.
Spectral AI (NAS:MDAI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Spectral AI 3-Year EBITDA Growth Rate Related Terms
MDAI vs ECOR, COCH, SNWV: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Spectral AI's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral AI 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Spectral AI's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -8.70% mean?
Spectral AI (MDAI) has a 3-Year EBITDA Growth Rate of -8.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spectral AI and its competitors. According to the industry distribution chart, Spectral AI ranks #523 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 75.8%.
Is Spectral AI's 3-Year EBITDA Growth Rate too high?
Spectral AI's current 3-Year EBITDA Growth Rate is -8.70%. Based on the distribution chart, Spectral AI ranks #523 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Spectral AI has a GF Score™ of 6/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral AI's 3-Year EBITDA Growth Rate compare to ECOR and COCH?
According to the Medical Devices & Instruments industry distribution chart, Spectral AI ranks #523 out of 690 companies for 3-Year EBITDA Growth Rate. This places Spectral AI in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spectral AI and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral AI's current 3-Year EBITDA Growth Rate is -8.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral AI stock overvalued right now?
Based on GuruFocus' analysis, Spectral AI (MDAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $1.60 — trading 92.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -8.70%. Spectral AI's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Spectral AI (MDAI), the current 3-Year EBITDA Growth Rate is -8.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral AI (MDAI) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral AI stock appears to be overvalued.
The current stock price of $1.60 is trading 92.8% above its estimated GF Value™ of $0.83.
GuruFocus considers Spectral AI to be Significantly Overvalued.
Key valuation signals for MDAI:
3-Year EBITDA Growth Rate: -8.70%
GF Value™: $0.83 vs. price of $1.60 (92.8% above fair value)
No single metric tells the full story. See the MDAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
6GF Score
Get the complete analysis for MDAI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDAI has been successfully added to your 
